Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inflammatory Mesenteric Disease and Sarcoidosis-like Reaction in a Patient with Lung Adenocarcinoma Who Received Pembrolizumab: Paraneoplastic Syndrome, Secondary to Checkpoint Inhibitor or Chance Finding?
Posado-Domínguez L, Escribano-Iglesias M, Bellido-Hernández L, León-Gil JG, Gómez-Muñoz MA, Gómez-Caminero López F, Martín-Galache M, Inés-Revuelta SM, Fonseca-Sánchez E. Posado-Domínguez L, et al. Among authors: bellido hernandez l. Curr Oncol. 2024 Nov 18;31(11):7319-7329. doi: 10.3390/curroncol31110540. Curr Oncol. 2024. PMID: 39590170 Free PMC article.
Response to platinum-based therapies in second-line after immunotherapy in advanced or metastatic non-small-cell lung cancer PD-L1 ≥50.
Olivares-Hernández A, Posado-Domínguez L, Redondo-González JC, Corvo-Félix L, Bellido Hernández L, Fonseca-Sánchez E, Del Barco-Morillo E. Olivares-Hernández A, et al. Among authors: bellido hernandez l. Transl Lung Cancer Res. 2024 Oct 31;13(10):2649-2659. doi: 10.21037/tlcr-24-513. Epub 2024 Oct 24. Transl Lung Cancer Res. 2024. PMID: 39507026 Free PMC article.
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Gómez Rueda A, Taus Á, Álvarez Álvarez R, Bernabé-Caro R, Chara L, López-Brea M, Vilà L, Sala González MÁ, Del Barrio Díaz Aldagalán A, Esteban Herrera B, López Castro R, Álvarez Cabellos R, Doménech M, Falagan S, Moreno Vega A, Aguado C, Barba A, Delgado Ureña MT, Isla D, Bellido Hernández L, Fírvida Pérez JL, Juan-Vidal Ó, Massutí B, Mielgo-Rubio X, Ortega AL, Catot S, Dómine M, Escoín-Pérez C, García Navalón F, Gil-Bazo I, Muñoz S, Rodríguez-Abreu D, Villatoro Roldán RM, Alonso-Jáudenes Curbera G, León-Mateos L, Padilla A, Paredes Lario A, Sánchez-Torres JM, Garrido P; Spanish Lung Cancer Group. Gómez Rueda A, et al. Among authors: bellido hernandez l. Clin Transl Oncol. 2024 Jul;26(7):1779-1789. doi: 10.1007/s12094-024-03404-9. Epub 2024 Mar 21. Clin Transl Oncol. 2024. PMID: 38512450
Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data.
Cañueto J, Muñoz-Couselo E, Cardona-Machado C, Becerril-Andrés S, Martín-Vallejo J, Serra-Guillén C, Soria A, Serrano-Domingo JJ, Ortiz-Velez C, Lostes J, García-Castaño A, Puig S, Fernández de Misa R, Medina J, Aguado C, Ayala de Miguel P, Navarro-Navarro I, Masferrer E, Delgado M, Bellido-Hernández L, Sanmartin O. Cañueto J, et al. Among authors: bellido hernandez l. J Eur Acad Dermatol Venereol. 2024 Aug;38(8):e666-e670. doi: 10.1111/jdv.19821. Epub 2024 Feb 3. J Eur Acad Dermatol Venereol. 2024. PMID: 38308557 No abstract available.
Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis.
Olivares-Hernández A, Roldán-Ruiz J, Miramontes-González JP, Toribio-García I, García-Hernández JL, Posado-Domínguez L, Bellido-Hernández L, Cruz-Hernández JJ, Fonseca-Sánchez E, Del Barco-Morillo E. Olivares-Hernández A, et al. Among authors: bellido hernandez l. Chin Clin Oncol. 2023 Dec;12(6):62. doi: 10.21037/cco-23-58. Chin Clin Oncol. 2023. PMID: 38195073 Free article.
Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data.
Toribio-García I, Olivares-Hernández A, Miramontes-González JP, Domínguez LP, Martín García A, Eiros Bachiller R, Figuero-Pérez L, Garijo Martínez M, Roldán Ruiz J, Bellido Hernández L, Fonseca-Sánchez E, Luis Sánchez P, Del Barco-Morillo E. Toribio-García I, et al. Among authors: bellido hernandez l. Cancers (Basel). 2023 Aug 28;15(17):4293. doi: 10.3390/cancers15174293. Cancers (Basel). 2023. PMID: 37686569 Free PMC article.
Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review.
Terán Brage E, Roldán Ruíz J, González Martín J, Oviedo Rodríguez JD, Vidal Tocino R, Rodríguez Diego S, Sánchez Hernández PL, Bellido Hernández L, Fonseca Sánchez E. Terán Brage E, et al. Among authors: bellido hernandez l. Curr Probl Cancer Case Rep. 2022 Jun;6:100153. doi: 10.1016/j.cpccr.2022.100153. Epub 2022 Mar 31. Curr Probl Cancer Case Rep. 2022. PMID: 35378738 Free PMC article.
Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis.
Olivares-Hernández A, Del Barco Morillo E, Parra Pérez C, Miramontes-González JP, Figuero-Pérez L, Martín-Gómez T, Escala-Cornejo R, Bellido Hernández L, González Sarmiento R, Cruz-Hernández JJ, Ludeña de la Cruz MD. Olivares-Hernández A, et al. Among authors: bellido hernandez l. Biomedicines. 2022 Feb 2;10(2):360. doi: 10.3390/biomedicines10020360. Biomedicines. 2022. PMID: 35203569 Free PMC article.
Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma.
García-Sancha N, Corchado-Cobos R, Bellido-Hernández L, Román-Curto C, Cardeñoso-Álvarez E, Pérez-Losada J, Orfao A, Cañueto J. García-Sancha N, et al. Among authors: bellido hernandez l. Cancers (Basel). 2021 Oct 13;13(20):5134. doi: 10.3390/cancers13205134. Cancers (Basel). 2021. PMID: 34680282 Free PMC article. Review.
Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors.
Olivares-Hernández A, Figuero-Pérez L, Amores Martín MA, Bellido Hernández L, Mezquita L, Vidal Tocino MDR, López Cadenas F, Gómez-Caminero López F, Escala-Cornejo RA, Cruz Hernández JJ. Olivares-Hernández A, et al. Among authors: bellido hernandez l. Case Rep Oncol Med. 2021 Feb 12;2021:6631859. doi: 10.1155/2021/6631859. eCollection 2021. Case Rep Oncol Med. 2021. PMID: 33628551 Free PMC article.
11 results